Balyasny Asset Management
EFTR

Balyasny Asset Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Balyasny Asset Management’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,628
Closed -$2.63M – 2528
2021
Q2 		$2.63M Hold
10,628
– – 0.01% 935
2021
Q1 		$2.58M Buy
+10,628
New +$2.61M 0.01% 941

Other funds holding EFTR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Balyasny Asset Management's EFTR Position: Q3 2021 in Review

Balyasny Asset Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 10,628 shares — an estimated $2.63M sold.

Balyasny Asset Management first reported a position in EFTR in Q1 2021 and held it in 2 quarters. The position peaked at $2.63M in Q2 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

  • Balyasny Asset Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 10,628 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $2.63M.
  • Balyasny Asset Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Balyasny Asset Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $2.63M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.